These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26301022)

  • 1. [Erlenmeyer flask deformity of the femur in Gaucher disease].
    Frikha F; Bahloul Z
    Pan Afr Med J; 2015; 20():418. PubMed ID: 26301022
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cathepsin K as a biomarker of bone involvement in type 1 Gaucher disease].
    Bobillo Lobato J; Durán Parejo P; Núñez Vázquez RJ; Jiménez Jiménez LM
    Med Clin (Barc); 2015 Oct; 145(7):281-7. PubMed ID: 25662720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying the Erlenmeyer flask deformity.
    Carter A; Rajan PS; Deegan P; Cox TM; Bearcroft P
    Br J Radiol; 2012 Jul; 85(1015):905-9. PubMed ID: 22010032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal aspects of Gaucher disease: a review.
    Wenstrup RJ; Roca-Espiau M; Weinreb NJ; Bembi B
    Br J Radiol; 2002; 75 Suppl 1():A2-12. PubMed ID: 12036828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlenmeyer flask.
    Tran HA
    J Clin Endocrinol Metab; 2004 Oct; 89(10):4827-8. PubMed ID: 15472170
    [No Abstract]   [Full Text] [Related]  

  • 6. Gaucher disease and bone manifestations.
    Marcucci G; Zimran A; Bembi B; Kanis J; Reginster JY; Rizzoli R; Cooper C; Brandi ML
    Calcif Tissue Int; 2014 Dec; 95(6):477-94. PubMed ID: 25377906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease.
    Drugan C; Jebeleanu G; Grigorescu-Sido P; Caillaud C; Craciun AM
    Blood Cells Mol Dis; 2002; 28(1):13-20. PubMed ID: 11814307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I Gaucher disease with bullous pemphigoid and Parkinson disease: A case report.
    Le Peillet D; Prendki V; Trombert V; Laffitte E; Assal F; Reny JL; Serratrice C
    Medicine (Baltimore); 2018 Mar; 97(13):e0188. PubMed ID: 29595653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic and histochemical investigation of Gaucher cells.
    Matsubara T; Yoshiya S; Maeda M; Shiba R; Hirohata K
    Clin Orthop Relat Res; 1982 Jun; (166):233-42. PubMed ID: 7083678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel manifestations of Farber disease mimicking neuronopathic Gaucher disease.
    Mhatre S; Muranjan M; Karande S; Balaji H
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34045195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S; Roberts A; Patterson MA; Amato D
    Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral symmetrical cortical osteolytic lesions in two patients with Gaucher disease.
    Oppenheim IM; Canon AM; Barcenas W; Groden C; Goker-Alpan O; Resnik CS; Sidransky E
    Skeletal Radiol; 2011 Dec; 40(12):1611-5. PubMed ID: 21935720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gaucher disease: an overview of clinical characteristics and therapy.
    Kingma W
    J Intraven Nurs; 1996; 19(2):79-82. PubMed ID: 8852167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging--initial experience.
    Maas M; van Kuijk C; Stoker J; Hollak CE; Akkerman EM; Aerts JF; den Heeten GJ
    Radiology; 2003 Nov; 229(2):554-61. PubMed ID: 14526090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
    J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole body MRI in type I Gaucher patients: evaluation of skeletal involvement.
    Poll LW; Cox ML; Godehardt E; Steinhof V; vom Dahl S
    Blood Cells Mol Dis; 2011 Jan; 46(1):53-9. PubMed ID: 21056931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gaucher disease diagnosed in pediatrics: an early bone involvement].
    Kennouche S; Bakir R
    Presse Med; 2009 Dec; 38 Suppl 2():2S50-2. PubMed ID: 20304307
    [No Abstract]   [Full Text] [Related]  

  • 18. Parkinsonism among Gaucher disease carriers.
    Goker-Alpan O; Schiffmann R; LaMarca ME; Nussbaum RL; McInerney-Leo A; Sidransky E
    J Med Genet; 2004 Dec; 41(12):937-40. PubMed ID: 15591280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement.
    Ciana G; Cuttini M; Bembi B
    N Engl J Med; 1997 Sep; 337(10):712. PubMed ID: 9280823
    [No Abstract]   [Full Text] [Related]  

  • 20. Type I Gaucher disease with severe skeletal destruction, extraosseous extension, and monoclonal gammopathy.
    Kaloterakis A; Cholongitas E; Pantelis E; Papadimitriou C; Durakis S; Filiotou A
    Am J Hematol; 2004 Dec; 77(4):377-80. PubMed ID: 15551278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.